Brian Culley - Mast Therapeutics CEO, Director
CEO
Mr. Brian M. Culley is Chief Executive Officer and Director of Mast Therapeutics Inc. He has served as principal executive officer since February 2009. Previously, from January 2007 to February 2010, has served as principal executive officer since February 2009. Previously, from January 2007 to February 2010, he served as chief business officer and senior vice president, from February 2006 to January 2007, he served as senior vice president, business development, and, from December 2004 to February 2006, he served as vice president, business development. From 2002 until 2004, Mr. Culley managed all strategic collaborations and licensing agreements for iTherx, Inc. in San Diego, where his most recent title was director of business development and marketing. From 1999 until 2000, he was a licensing and marketing associate at the University of California, San Diego, department of technology transfer intellectual property services and from 1996 to 1999, he was a research associate for Neurocrine Biosciences, Inc since 2011.
| Age | 42 |
| Tenure | 13 years |
| Professional Marks | MBA |
| Phone | 858-552-0866 |
| Web | http://www.masttherapeutics.com |
Mast Therapeutics Management Efficiency
Mast Therapeutics' management efficiency ratios could be used to measure how well Mast Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 14.74 M in liabilities with Debt to Equity (D/E) ratio of 1.08, which is about average as compared to similar companies. Mast Therapeutics has a current ratio of 1.32, which is within standard range for the sector. Debt can assist Mast Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Mast Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Mast Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Mast to invest in growth at high rates of return. When we think about Mast Therapeutics' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 10 records | CEO Age | ||
| Alexander J | Fortress Transp Infra | N/A | |
| Bradley Soultz | Willscot Mobile Mini | 55 | |
| Kathryn Marinello | Herc Holdings | 59 | |
| Lawrence Silber | Herc Holdings | 67 | |
| John Tague | Herc Holdings | 52 | |
| Tom Kelly | AerCap Holdings NV | 56 | |
| Michael Kneeland | United Rentals | 67 | |
| Jeffrey Sagansky | Willscot Mobile Mini | 66 | |
| Frank Martell | Loandepot | 64 | |
| Matthew Flannery | United Rentals | 59 | |
Management Performance
| Return On Asset | -0.0045 |
Mast Therapeutics Leadership Team
Elected by the shareholders, the Mast Therapeutics' board of directors comprises two types of representatives: Mast Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mast. The board's role is to monitor Mast Therapeutics' management team and ensure that shareholders' interests are well served. Mast Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mast Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gregory Gorgas, Senior Vice President - Commercial | ||
| Peter Greenleaf, Independent Director | ||
| Brian Culley, CEO, Director | ||
| Brandi Roberts, CFO, Senior Vice President Principal Accounting Officer, Principal Financial Officer | ||
| Lewis Shuster, Independent Director | ||
| Howard Dittrich, Independent Director | ||
| Matthew Pauls, Independent Director | ||
| Edwin Parsley, Chief Medical Officer & Senior Vice President | ||
| David Ramsay, Independent Director | ||
| Martin Emanuele, Senior Vice President - Development |
Mast Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Mast Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.0045 | |||
| Profit Margin | (0.29) % | |||
| Operating Margin | (0.17) % | |||
| Current Valuation | 51.07 M | |||
| Shares Outstanding | 254.75 M | |||
| Shares Owned By Insiders | 0.26 % | |||
| Shares Owned By Institutions | 22.90 % | |||
| Number Of Shares Shorted | 7.1 M | |||
| Price To Earning | (0.76) X | |||
| Price To Book | 3.64 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Mast Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Mast Therapeutics' short interest history, or implied volatility extrapolated from Mast Therapeutics options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Other Consideration for investing in Mast Stock
If you are still planning to invest in Mast Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Mast Therapeutics' history and understand the potential risks before investing.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Stocks Directory Find actively traded stocks across global markets | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |